Apricus Biosciences, Inc.
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros® and Erectile Dysfunction Population
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subheadof the release, "2H 2016"should instead be "Q32016."
The corrected release follows:
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
Vitaros U.S. NDA Re-Submission Remains on Schedule for Q32016
SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced it will host a Vitaros®and erectile dysfunction (“ED”) key opinion leader event on Monday, May 9th, from 11:00 a.m. to 12:00 noon ET.
The meeting will feature a presentation by Edward D. Kim, M.D., Professor, Division of Urology at The University of Tennessee Graduate School of Medicine, Knoxville, TN. Dr. Kim will address the current status of treatment options in the ED population, unmet patient need based on contraindications or suboptimal response to currently available systemic treatments, provide an overview of the clinical data for Vitaros, and discuss where a non-systemic, topical treatment in the ED patient population may add value.
A live webcast with presentation slides and subsequent replay of the event will be available atwww.apricusbio.com. If you would like to ask a question during the live Q&A, please submit your request via email email@example.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. To participate by telephone, please dial (877) 841-3961 (Domestic) or (201) 689-8589 (International). The conference ID number is 13633850. The archived webcast will remain available for 30 days following the live presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.
For further information on Apricus, visithttp://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Crown Bioscience Inc.17.11.2017 18:09 | pressemeddelelse
CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research
Barings17.11.2017 17:02 | pressemeddelelse
Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa
Vicor Corporation16.11.2017 23:31 | pressemeddelelse
At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking
ELS Educational Services, Inc.16.11.2017 21:01 | pressemeddelelse
ELS Educational Services, Inc. Launches New Vacation English Program Starting January 2018
Aryaka16.11.2017 16:04 | pressemeddelelse
Global SD-WAN Partnership between CallTower and Aryaka to Deliver High-Performance Cloud Communication Solutions to Global Enterprises
Gunvor Group Ltd16.11.2017 15:01 | pressemeddelelse
Gunvor Secures US $1.39 Billion Revolving Credit Facility
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum